Has Lawrence Sher, MD received payments from drug or device companies?

Yes. Drug and device makers reported $38,442,159 in general payments to Lawrence Sher, MD across 6,007 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lawrence Sher, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lawrence Sher, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lawrence Sher, MD

Pediatrics · Rolling Hills Estates, CANPI 1912923913

Payments from drug & device makers

$38,442,159in general payments, 2019–2025

Across 6,007 payments — averaging $6399.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$10.3M
Sanofi Pasteur Inc.$8.9M
Modernatx, Inc.$8.2M
Eli Lilly$3M
Regeneron$2.5M
AstraZeneca$2.4M
plus $3M from 45 others

$1,134,904in research payments, 2019–2025

Across 323 payments — averaging $3513.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Ichnos Glenmark Innovation Inc$714K
Glenmark Pharmaceuticals Inc., USA$320K
Eli Lilly$25K
Regeneron$22K
Sanofi$20K
Pfizer$18K
plus $14K from 2 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	274	$10,329,378
Sanofi Pasteur Inc.	250	$8,945,901
Modernatx, Inc.	4,260	$8,236,844
Eli Lilly	39	$2,967,895
Regeneron	231	$2,516,775
AstraZeneca	77	$2,419,541
Sanofi US Services Inc.	104	$593,271
LEO Pharma AS	28	$471,734
Merck	17	$349,183
Astrazeneca AB	4	$291,097
Aimmune Therapeutics, Inc.	35	$213,740
Teva Pharmaceuticals USA, Inc.	28	$160,999
Sanofi	89	$138,358
Incyte Corporation	33	$123,817
Regeneron Healthcare Solutions, Inc.	122	$121,433
GSK	106	$109,145
Genentech, Inc.	16	$99,087
Amgen(2 entities)	17	$63,344
Invivyd Inc	2	$58,323
Cipla USA Inc.	25	$43,657
Otsuka Pharmaceutical Development & Commercialization, Inc.	2	$42,605
Novartis	14	$39,759
AbbVie(2 entities)	107	$38,511
Sanofi-aventis U.S. LLC	11	$24,180
Shire North American Group Inc	8	$23,042
Roche Molecular Systems, Inc.	13	$12,809
LEO Pharma Inc.	4	$4,261
Cepheid	1	$1,000
ARS Pharmaceuticals Operations, Inc.	3	$375
Optinose US, Inc.	2	$305
Takeda Pharmaceuticals U.S.A., Inc.	13	$211
Genentech USA, Inc.	9	$202
Boehringer Ingelheim	8	$202
Organon	3	$191
Corium, LLC	10	$172
Novo Nordisk	6	$130
Johnson & Johnson	4	$110
Lilly USA, LLC	4	$91
Neos Therapeutics, LP	5	$82
Kaleo, Inc.	4	$74
Dermavant Sciences, Inc.	2	$69
Cranial Technologies, Inc	3	$44
Supernus Pharmaceuticals, Inc.	3	$42
Arbor Pharmaceuticals, Inc.	2	$29
Phadia US Inc.	2	$29
Avanir Pharmaceuticals, Inc.	2	$27
Biohaven Pharmaceuticals, Inc.	1	$23
Biohaven Pharmaceutical Holding Company Ltd.	1	$22
Bayer	1	$17
Kowa Pharmaceuticals America, Inc.	1	$14
Antares Pharma, Inc.	1	$12

How this compares

$38,442,159 in reported general payments places this provider in the 95th percentile of 5,539 pediatrics providers in California.

See all pediatrics providers in California →

Medicare billing

Part B allowed, 2024

$105,021

Medicare patients

186

Services billed

2,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pediatrics in Rolling Hills Estates

Nicola KleinOakland$81.9M
Carey ChronisVentura$6.3M
Jose DiazDowney$5.4M
Bruce BuckinghamSan Jose$3.1M
Patrick WalshAnaheim$3M
Teresita Salazar-GuadizBellflower$2.7M
Liberation de LeonParamount$2.7M
Melvin HeymanSan Francisco$2.5M
Aftab NazMadera$2.3M
Maricor GrioMission Hills$2.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →